talquetamab
janssen
['talquetamab']
talquetamab plays to a packed house at #ash2022! ph2 data shows 73% overall response in heavily pretreated rrmm, 63% in pts who had received previous t cell redirectors, with low rates of infection and good tolerability. ph3 trial already ongoing. 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.